=> d his

(FILE 'HOME' ENTERED AT 14:43:04 ON 30 MAR 2005)

FILE 'REGISTRY' ENTERED AT 14:43:12 ON 30 MAR 2005
L1 STRUCTURE UPLOADED
L2 39 S L1
L3 5103 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:44:35 ON 30 MAR 2005
L4 5315 S L3
L5 4860 S L4 AND PY<2000
L6 52 S L5 AND THU/RL

=> d que l6 stat
L1 STR



G1 O,S,N,CH2
G2 OH,SO3H,[@1],[@2],[@3],[@4]

Structure attributes must be viewed using STN Express query preparation.
L3 5103 SEA FILE=REGISTRY SSS FUL L1
L4 5315 SEA FILE=CAPLUS ABB=ON PLU=ON L3
L5 4860 SEA FILE=CAPLUS ABB=ON PLU=ON L4 AND PY<2000
L6 52 SEA FILE=CAPLUS ABB=ON PLU=ON L5 AND THU/RL

=> d 1-52 bib abs hitstr

L6 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:874766 CAPLUS
DN 139:354473
TI Promoting whole body health with topical oral compositions containing antimicrobials
IN Doyle, Matthew Joseph; Hunter-Rinderle, Stephen Joseph; Glandorf, William Michael; White, Donald James
PA The Procter & Gamble Company, USA
SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 39,620.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003206874	A1	20031106	US 2003-454843	20030605
	US 5939052	A	19990817	US 1996-754577	19961121 <--
	US 6350436	B1	20020226	US 1999-451420	19991130
	US 6555094	B1	20030429	US 2000-710440	20001110
	US 2002106336	A1	20020808	US 2001-39620	20011024
	US 6667027	B2	20031223		
	US 2003152527	A1	20030814	US 2003-351205	20030124
	US 6821507	B2	20041123		
PRAI	US 1996-754577	A2	19961121		
	US 1998-203216	B2	19981130		
	US 1999-451420	A3	19991130		
	US 2000-607240	A2	20000630		
	US 2000-710440	A2	20001110		
	US 2001-39620	A2	20011024		
	US 1999-165350P	P	19991112		

AB The present invention relates to promoting whole body health by using topical oral compns. comprising an antimicrobial agent, in particular stannous salts, such as stannous fluoride and stannous chloride in combination with a polymeric mineral surface active agent such as condensed polyphosphates or polyphosphonates. In addition to providing a spectrum of intraoral benefits, topical administration of the present compns. to the oral cavity surprisingly provides benefits to systemic health. In particular, the present invention relates to methods of using the present topical oral compns. to reduce the risk in development of cardiovascular disease, stroke, atherosclerosis, diabetes, severe respiratory infections, premature births and low birth weight, post-partum dysfunction in neurol. and developmental functions, and associated increased risk of mortality. For example, a mouthwash composition contained flavor 0.05, FD&C Blue number 1 0.02, Na saccharin 0.06, glycerin 7.5, stannous chloride 0.2, cetylpyridinium chloride 0.045, polyphosphonate 0.5, Na gluconate, ethanol 14.46, and water balance to 100 %.
IT 87-17-2, Salicylanilide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:521916 CAPLUS
DN 135:107152
TI Preparation of N,N'-diphenyl ureas as IL-8 receptor antagonists
IN Widdowson, Katherine Louise; Veber, Daniel Frank; Jurewicz, Anthony Joseph; Hertzberg, Robert Philip; Rutledge, Melvin Clarence, Jr.
PA Smithkline Beecham Corp., USA
SO U.S., 51 pp., Cont.-in-part of U.S. 58,86,044.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6262113	B1	20010717	US 1998-125279	19980814
	US 5886044	A	19990323	US 1996-641990	19960320 <--
	WO 9729743	A1	19970821	WO 1996-US13632	19960821 <--
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 2002128321	A1	20020912	US 2001-871076	20010531
PRAI	US 1996-641990	A2	19960320		
	WO 1996-US13632	W	19960821		
	US 1995-390260	B2	19950217		
	WO 1996-US2260	A	19960216		
	US 1998-125279	A3	19980814		

OS MARPAT 135:107152
GI



I

AB The title compds. [I; X = O; X1 = O, S; R1 = H, halo, NO2, etc.; two R1 moieties together may form O(CH2)sO, 5-6 membered unsatd. ring; s = 1-3; Y = H, halo, NO2, etc.; two Y moieties together may form O(CH2)sO, 5-6 membered unsatd. ring; n, m = 1-3], useful for treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 α or β receptor, were prepared Thus, reacting Me 4-amino-3-hydroxybenzoate with Ph isocyanate afforded 90% I [X = O; R = OH; R1 = 4-CO2Me; m = 1; Y = H]. All of the exemplified compds. I showed an IC50 from about 45 to about < 1 μg/mL against IL-8 receptor binding. All of these compds. were also found to be inhibitors of Gro-α binding at about the same level.
IT 182499-16-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N,N'-diphenyl ureas as IL-8 receptor antagonists)
RN 182499-16-7 CAPLUS
CN Benzamide, 3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 87-17-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N,N'-diphenyl ureas as IL-8 receptor antagonists)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



IT 1214-44-4P 68507-91-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N,N'-diphenyl ureas as IL-8 receptor antagonists)
RN 1214-44-4 CAPLUS
CN Benzamide, 3-amino-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 68507-91-5 CAPLUS
CN Benzamide, 2-hydroxy-3-nitro-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:140255 CAPLUS
DN 133:26374
TI The pharmacology of halogenated salicylanilides and their anthelmintic use in animals
AU Swan, G. E.
CS Department of Pharmacology and Toxicology, Faculty of Veterinary Science, Univ. of Pretoria, Onderstepoort, 0110, S. Afr.
SO Journal of the South African Veterinary Association (1999), 70(2), 61-70
CODEN: JAVTAP; ISSN: 0038-2809
PB South African Veterinary Association
DT Journal; General Review
LA Afrikaans
AB A review with 127 refs. The halogenated salicylanilides are a large group of compds. developed mainly for their antiparasitic activity in animals. Several halogenated salicylanilides with potent antiparasitic activity have been synthesized of which only closantel, niclosamide, oxyclozanide, rafoxanide and resorantel are com. available. Closantel and rafoxanide, which represent the most important drugs in the group, are used extensively for the control of Haemonchus spp. and Fasciola spp. infestations in sheep and cattle and Oestrus ovis in sheep in many parts of the world. Niclosamide is used extensively for its anticestodal activity in a wide range of animals. Antiparasitic activity of the halogenated salicylanilides has also been demonstrated against a large number of other internal parasites, in particular hematophagous helminths, and external parasites including ticks and mites, in a variety of animal species. Several cases of toxicity and mortality have been reported for closantel and rafoxanide in sheep and goats. Their unique pharmacokinetic behavior appears to play an important role in the efficacy and safety of these compds. The chemical and phys. characteristics, mode of action, pharmacokinetics, antiparasitic activity and toxicity of the halogenated salicylanilides in animals are reviewed.
IT 87-17-2D, Salicylanilide, halogenated derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of halogenated salicylanilides and their anthelmintic use in animals)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:102429 CAPLUS
DN 132:245849
TI Use of reversed-phase high-performance liquid chromatography in QSAR analysis of 2,4-dihydroxythiobenzanilide analogs
AU Jozwiak, K.; Szumilo, H.; Senczyna, B.; Niewiadomy, A.
CS Department of Inorganic and Analytical Chemistry, Medical University of Lublin, Lublin, 20-081, Pol.
SO SAR and QSAR in Environmental Research (1999), 10(6), 509-532
CODEN: SQERED; ISSN: 1062-936X
PB Gordon & Breach Science Publishers
DT Journal
LA English
AB Thiobenzanilides are found to show strong biol. activity as antimicrobial, antimycotic, and tuberculostatic agents. In addition, they are relatively weakly toxic to higher organisms. A large set of new (N-phenyl-)-2,4-dihydroxybenzenecarbothioamide derivs. was obtained. Preliminary studies showed high microbiol. action of some of them. In the process of chromatog. anal., several different chromatog. parameters were obtained. In case of RP-HPLC, these parameters correspond to hydrophobicity of the solute. Obtained chromatog. parameters exhibited moderate correlation with calculated log P parameter. Linear dependence of bacteriostatic or fungostatic activity on lipophilicity was observed The degree of correlation of different parameters was compared. The lipophilicity of analyzed tioamides was the most important factor responsible for fungostatic and bacteriostatic activity. In comparison to methanol eluent system, chromatog. parameters obtained in acetonitrile system were better correlated with bioactivity. Conversely with the calculated log P values, the exptl. derived parameters exhibited significant higher correlation to fungostatic activity determined on dermatophytes. While in case of other tested microorganisms log P was comparably or sometimes slightly better correlated.
IT 181875-13-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reversed-phase HPLC in QSAR anal. of dihydroxythiobenzanilide analogs as antimicrobial agents)
RN 181875-13-8 CAPLUS
CN Benzenecarbothioamide, 2,4-dihydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:672505 CAPLUS
DN 131:277031
TI Blooming type germicidal hard-surface cleaners
IN Cheung, Tak Wai; Smialowicz, Dennis Thomas
PA Reckitt and Colman Inc., USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952361	A1	19991021	WO 1999-US5958	19990318 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	GB 2336312	A1	19991020	GB 1998-7668	19980414 <--
	GB 2336312	B2	20030521		
	US 6395697	B1	20020528	US 1999-261691	19990303
	CA 2328206	AA	19991021	CA 1999-2328206	19990318 <--
	AU 9931002	A1	19991101	AU 1999-31002	19990318 <--
	AU 747996	B2	20020530		
	BR 9909586	A	20001212	BR 1999-9586	19990318
	EP 1071324	A1	20010131	EP 1999-912681	19990318
	EP 1071324	B1	20040211		
	R: BE, DE, ES, FR, GB, IT, NL				
PRAI	GB 1998-7668	A	19980414		
	WO 1999-US5958	W	19990318		

OS MARPAT 131:277031
AB Aqueous concentrated liquid disinfectant compns. include: a microbicide, other than a quaternary ammonium compound, having germicidal properties; an organic solvent; a binary co-solvent system comprising an alkyl biphenyl solvent and a co-solvent; and optionally, but desirably, at least one optional constituent. The concentrate compns. feature excellent blooming characteristics. The microbicides are chloramine, iodine, a iodophor, a chlorhexidine salt, parachlorometaxylenol, hexachlorophene, 2-bromo-2-nitropropanediol, salicylanilide, 3,3',4',5-tetrachlorosalicylanilide, 3',4',5-trichlorosalicylanilide,3,5-dibromo-3'-trifluoromethylsalicylanilide, 3,4,4'-trichlorocarbanilide and 2,4,4'-trichloro-2'-hydroxydiphenyl ether.
IT 87-17-2, Salicylanilide
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(blooming-type germicidal hard-surface disinfectants containing)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:571447 CAPLUS
DN 131:295129
TI Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria
AU Ellsworth, Edmund L.; Olson, Eric R.; Showalter, H. D. Hollis
CS Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, USA
SO Chemtracts (1999), 12(9), 656-661
CODEN: CHEMFW; ISSN: 1431-9268
PB Springer-Verlag New York Inc.
DT Journal; General Review
LA English
AB The title research of M. J. Macielag, et al. (1998) is reviewed with commentary and 15 refs.
IT 87-17-2DP, Salicylanilide, derivs 4214-48-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 4214-48-6 CAPLUS
CN Benzamide, 3,5-dichloro-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:549130 CAPLUS
DN 131:161675
TI Curable compositions with antimicrobial properties
IN Montgomery, R. Eric; Nathoo, Salim A.
PA Oraceutical, LLC, USA
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9942080	A2	19990826	WO 1999-US3651	19990219 <--
	WO 9942080	A3	19991007		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9933038	A1	19990906	AU 1999-33038	19990219 <--
	EP 1056430	A2	20001206	EP 1999-934240	19990219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6281265	B1	20010828	US 1999-255450	19990219
	US 2001056133	A1	20011227	US 2001-909157	20010719
	US 2003220416	A1	20031127	US 2003-401095	20030327
PRAI	US 1998-75176P	P	19980219		
	US 1998-75246P	P	19980219		
	US 1998-94823P	P	19980731		
	US 1999-255450	A3	19990219		
	WO 1999-US3651	W	19990219		
	US 2001-909157	B3	20010719		

AB Novel curable compns. are disclosed which include a water insol. antimicrobial agent. The curable compns. are useful in inhibiting the growth of bacteria on the surface of the curable composition, within the curable compns. and in a volume adjacent to the curable composition Herculite XRV restorative material was modified to include triclosan. The antimicrobial activity of triclosan was demonstrated after release into bacteria media.
IT 87-17-2D, Salicylanilide, halo derivs.
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(curable dental compns. with antimicrobial properties)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:549129 CAPLUS
DN 131:161674
TI Antimicrobial denture adhesive composition
IN Montgomery, R. Eric; Wolf, Robert O.
PA Oraceutical, LLC, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9942079	A2	19990826	WO 1999-US3588	19990219 <--
	WO 9942079	A3	19991014		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2321192	AA	19990826	CA 1999-2321192	19990219 <--
	AU 9927744	A1	19990906	AU 1999-27744	19990219 <--
	AU 756369	B2	20030109		
	EP 1056429	A2	20001206	EP 1999-908266	19990219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6281265	B1	20010828	US 1999-255450	19990219
	JP 2002503520	T2	20020205	JP 2000-532096	19990219
	US 2001056133	A1	20011227	US 2001-909157	20010719
	US 2003220416	A1	20031127	US 2003-401095	20030327
PRAI	US 1998-75176P	P	19980219		
	US 1998-75246P	P	19980219		
	US 1998-94823P	P	19980731		
	US 1999-255450	A3	19990219		
	WO 1999-US3588	W	19990219		
	US 2001-909157	B3	20010719		

AB Novel curable compns. are disclosed which include a water insol. antimicrobial agent. The curable compns. are useful in inhibiting the growth of bacteria on the surface of the curable composition, within the curable compns. and in a volume adjacent to the curable composition Com. available permanent restorative Herculite XRV was modified to include water-insol. triclosan. Triclosan was release into surrounding media in sufficiently high concs. to inhibit growth of Streptococcus mutans and Pseudomonas aeruginosa.
IT 87-17-2D, Salicylanilide, halo derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial denture adhesive composition)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:481293 CAPLUS
DN 131:129759
TI Preparation of aniline derivatives as calcium release-activated calcium channel inhibitors and their uses
IN Kubota, Koichi; Funatsu, Masashi; Kanzawa, Keizo; Ishikawa, Atsushi; Takeuchi, Makoto
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11209328	A2	19990803	JP 1998-10147	19980122 <--
PRAI JP 1998-10147		19980122		

OS MARPAT 131:129759
GI



I

AB The derivs. I [R1 = OH, lower alkoxy, lower alkanoyloxy; R2, R3, R4 = H, halo, lower alkyl, lower alkoxy, lower alkanoyloxy, NO2, cyano, OH; R5 = H, lower alkyl; R6 = H, halo, lower alkyl, lower alkoxy, lower alkanoyloxy, NO2, cyano, OH, NH2, lower alkanoylamino; X = CO, CH2; combination of groups is selected from the following: (1) R1 = OH, R4 = OMe, R5 = H, X = CO, R6 = Cl; (2) R1 = OH, R2 = Br, R4 = H, X = CO, R5 = H, lower alkyl; (3) R1 = OMe, OCOMe, R2 = Br, R4 = H, X = CO, R6 = H, halo, lower alkyl, lower alkoxy; and (4) R1 = OH, R2 = R3 = R4 = H, R4 = Cl, X = CH2, R6 = Cl] are prepared Ca release-activated Ca channel inhibitors containing I or their pharmaceutically acceptable salts as active ingredients are also claimed. The inhibitors are useful for treatment of inflammatory diseases such as rheumatoid arthritis, allergy, tissue injury, proliferative diseases, etc. IC50 of I (R1 = OH, R2 = R4 = H, R3 = Cl, R6 = 4-Cl, X = CO) against Ca-release activated Ca channel of Jurkat T-cells was 0.20 μM.
IT 4638-48-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-benzylanilines or benzanilides as Ca release-activated Ca
channel inhibitors for treatment of inflammation and allergy)
RN 4638-48-6 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 10 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:434727 CAPLUS
DN 131:208587
TI Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems
AU Hilliard, Jamese J.; Goldschmidt, Raul M.; Licata, Lisa; Baum, Ellen Z.; Bush, Karen
CS The R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, 08869, USA
SO Antimicrobial Agents and Chemotherapy (1999), 43(7), 1693-1699
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB Many pathogenic bacteria utilize two-component systems consisting of a histidine protein kinase (HPK) and a response regulator (RR) for signal transduction. During the search for novel inhibitors, several chemical series, including benzoxazines, benzimidazoles, bis-phenols, cyclohexenes, trityls, and salicylanilides, were identified that inhibited the purified HPK-RR pairs KinA-Spo0F and NRII-NR1, with 50% inhibitory concns. (IC50s) ranging from 1.9 to >500 μM and MICs ranging from 0.5 to >16 μg/mL for gram-pos. bacteria. However, addnl. observations suggested that mechanisms other than HPK inhibition might contribute to antibacterial activity. In the present work, representative compds. from the six different series of inhibitors were analyzed for their effects on membrane integrity and macromol. synthesis. At 4 + MIC, 17 of 24 compds. compromised the integrity of the bacterial cell membrane within 10 min, as measured by uptake of propidium iodide. In this set, compds. with lower IC50s tended to cause greater membrane disruption. Eleven of 12 compds. inhibited cellular incorporation of radiolabeled thymidine and uridine >97% in 5 min and amino acids >80% in 15 min. The HPK inhibitor that allowed >25% precursor incorporation had no measurable MIC (>16 μg/mL). Fifteen of 24 compds. also caused hemolysis of equine erythrocytes. Thus, the antibacterial HPK inhibitors caused a rapid decrease in cellular incorporation of RNA, DNA, and protein precursors, possibly as a result of the concomitant disruption of the cytoplasmic membrane. Bacterial killing by these HPK inhibitors may therefore be due to multiple mechanisms, independent of HPK inhibition.
IT 87-17-2D, Salicylanilide, analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:417986 CAPLUS
DN 131:87716
TI Preparation of sulfonamides as eosinophil function inhibitors, antiallergy agents, and antiasthmatic agents
IN Miyakawa, Motonori; Murai, Satoshi; Ishige, Hirohide; Suda, Masahiro; Fujimoto, Kyoko; Watanuki, Mitsuru; Nakamura, Tsutomu
PA Kaken Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 83 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11180945	A2	19990706	JP 1997-346815	19971216 <--
PRAI	JP 1997-346815		19971216		

OS MARPAT 131:87716
AB R1XYNR2SO2ZCONR3R4 [R1-R3 = H, C1-9 alkyl, C3-7 cycloalkyl, (un)substituted aryl, (un)substituted heterocyclyl, etc.; X = SO2NH, CONH, NHCONH, NHCSNH; Y = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene,; Z = phenylene, heterocyclylene; R4 = H, C1-9 alkyl, sulfonyl, Ph, (un)substituted heterocyclyl, etc.], their salts, their hydrates, or their solvates are prepared Their synthetic intermediates are also claimed. 4-ClC6H4SO2NH(CH2)2NPhSO2C6H4CO2H-2 (11.8 g) was chlorinated with SOCl2 and amidated with 4.6 g Et m-aminobenzoate to give 10.7 g of the corresponding amide, which at 0.1 μM inhibited 97.9% release of eosinophil peroxidase.
IT **230304-25-3P 230304-27-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as eosinophil function inhibitors, antiallergy agents, and antiasthmatic agents)
RN 230304-25-3 CAPLUS
CN Benzoic acid, 2-[[[2-[[2-[[[2-[[(4-chlorophenyl)sulfonyl]amino]ethyl]phenylamino]sulfonyl]benzoyl]amino]ethyl]phenylamino]carbonyl]- (9CI) (CA INDEX NAME)



RN 230304-27-5 CAPLUS
CN Benzoic acid, 2-[[[2-[[2-[[[2-[[(4-bromophenyl)sulfonyl]amino]ethyl]phenylamino]sulfonyl]benzoyl]amino]ethyl]phenylamino]carbonyl]- (9CI) (CA INDEX

L6 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
NAME)



L6 ANSWER 12 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:266970 CAPLUS
DN 131:96876
TI Reversed - phase HPTLC and structure - activity relationship for fungicidal substances
AU Rozylo, Jan. K.; Zabinska, Anna; Matysiak, Joanna; Niewiadomy, Andrzej
CS Faculty of Chemistry, M. Curie-Sklodowska University, Lublin, Pol.
SO Chemical & Environmental Research (1998), 7(1 & 2), 65-75
CODEN: CEREEH; ISSN: 0971-2151
PB Muslim Association for the Advancement of Science
DT Journal
LA English
AB TLC parameters were used in quant. structure-activity relationship studies (QSAR) for the prediction of biol. activity of new resynthesized bioactive compds. The retention behavior of fifteen antimycotic agents from the group of dihydroxythiobenzanilides in a reversed- phase high-performance thin- layer chromatog. (RP-HPTLC) system has been examined Using water-acetone as the mobile phase, the linear relationship between the volume fraction of the organic modifier and the logarithm of the capacity factor over a limited range was established for every solute. It was shown that the theor. capacity factor obtained by extrapolation of retention data in binary solvent system to pure aqueous eluent was suitable for quant. description of the hydrophobic nature of solutes in a way which is closely related to the calculated partition coefficient of the standard n-octanol-water partitioning system. Deviations from this relationship were found for the compds. with substituents which exert strong intramol. interactions. The equation describing the structure-activity relationship indicated the importance of hydrophobic character and structure of substituents in determining the antimycotic activity of examined compds.
IT **181875-13-8**
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(Reversed - phase HPTLC and structure - activity relationship for fungicidal substances)
RN 181875-13-8 CAPLUS
CN Benzenecarbothioamide, 2,4-dihydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:205323 CAPLUS
DN 130:267221
TI Preparation of phenylureas as IL-8 receptor antagonists
IN Widdowson, Katherine Louise; Veber, Daniel Frank; Jurewicz, Anthony Joseph; Hertzberg, Robert Phillip; Rutledge, Melvin Clarence, Jr.
PA Smithkline Beecham Corporation, USA
SO U.S., 43 pp., Cont.-in-part of U.S. Ser. No. 390,260, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5886044	A	19990323	US 1996-641990	19960320 <--
	US 5780483	A	19980714	US 1996-701299	19960821 <--
	US 6211373	B1	20010403	US 1998-111663	19980708
	US 6262113	B1	20010717	US 1998-125279	19980814
	US 6180675	B1	20010130	US 1999-240354	19990129
PRAI	US 1995-390260	B2	19950217		
	WO 1996-US2260	W	19960216		
	US 1996-641990	A2	19960320		
	US 1996-701299	A3	19960821		
	WO 1996-US13632	W	19960821		

OS MARPAT 130:267221
GI



I

AB The title compds. [I; X = O, S; R = OH; R1 = H, halo, NO2, etc.; Y = H, halo, CN, etc.; n = 1-3; m = 1-3], useful in the treatment of disease states mediated by the chemokine, interleukin-8 (IL-8), such as psoriasis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, ARDS, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, restenosis, angiogenesis, glomerulonephritis, thrombosis, Alzheimer's disease, graft vs. host reaction, allograft rejection, etc., were prepared E.g., reaction of Me 4-amino-3-hydroxybenzoate with Ph isocyanate afforded 90% I [R = OH; R1 = 4-(MeOCO); Y = H; m = 1]. All exemplified compds. I showed IC50 from 45 to <1 μM/mL for IL-8 receptor inhibition. Compds. I were also found to be inhibitors of Gro-α binding at about the same level.
IT **182499-16-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylureas as IL-8 receptor antagonists)
RN 182499-16-7 CAPLUS
CN Benzamide, 3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 87-17-2, 2-Phenylaminocarbonylphenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenylureas as IL-8 receptor antagonists)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



IT 1214-44-4P 68507-91-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylureas as IL-8 receptor antagonists)
RN 1214-44-4 CAPLUS
CN Benzamide, 3-amino-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 68507-91-5 CAPLUS
CN Benzamide, 2-hydroxy-3-nitro-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:197725 CAPLUS
DN 131:78223
TI List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness
CS Food and Drug Administration, HHS, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, Rockville, MD, 20857, USA
SO Federal Register (1999), 64(44), 10944-10947, 8 Mar 1999
CODEN: FEREAC; ISSN: 0097-6326
PB Superintendent of Documents
DT Journal
LA English
AB The Food and Drug Administration (FDA) is amending its regulations to include a list of drug products that may not be used for pharmacy compounding under the exemptions under section 503A of the Federal Food, Drug, and Cosmetic Act because they have had their approval withdrawn or were removed from the market because the drug product or its components have been found to be unsafe or not effective. The list has been compiled under the new statutory requirements of the Food and Drug Administration Modernization Act of 1997 (Modernization Act).
IT 2577-72-2, Metabromsalan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stds. for drug products that have been withdrawn or removed from market for safety or effectiveness reasons)
RN 2577-72-2 CAPLUS
CN Benzamide, 3,5-dibromo-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:188914 CAPLUS
DN 130:227737
TI Oral compositions containing bactericides and calcium carbonate
IN Suga, Yoshio; Ogawa, Yuka
PA Sunstar Inc., Japan
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5882631	A	19990316	US 1998-65609	19980424 <--
	JP 10330233	A2	19981215	JP 1997-161807	19970603 <--
	JP 3482323	B2	20031222		
	CN 1204506	A	19990113	CN 1998-115087	19980424 <--
	JP 11310522	A2	19991109	JP 1998-131074	19980424 <--
PRAI	JP 1997-123403	A	19970424		
	JP 1997-161807	A	19970603		
	JP 1998-63971	A	19980227		

AB Oral compns. containing a water-insol. noncationic bactericide showing improved stability with time and improved rheol. properties, and exerting excellent effects of eliminating dental plaque, preventing halitosis and eliminating tooth-staining substances. Addition of porous calcium carbonate to the oral compns. makes it possible to prevent the decrease in the bactericidal activity of water-insol. noncationic bactericides such as triclosan and improve the stability thereof while exerting excellent effects of eliminating dental plaque, preventing halitosis and eliminating tooth-staining substances. Furthermore, addition of sodium CM-cellulose to the oral compns. makes it possible to improve rheol. properties and stability with time. A liquid dentifrice was prepared in a conventional manner and packed in a PET resin container. The composition contained anhydrous silica 20.0, porous calcium carbonate 0.5, (average primary particle diameter:0.05 mm, bulk d.: 0.1 g/mL, BET sp. surface area: 90 m2), sorbitol 25.0, glycerin 12.0, carrageenan 1.0, sodium lauryl sulfate 1.5, sodium benzoate 0.2, saccharin sodium 0.1, flavor 0.5, triclosan 0.3, dl-a-tocopherol acetate 0.5, PEG-PPG block copolymer 1.5, sodium silicate 0.5, and purified water to 100.0%.
IT 87-17-2, Salicylanilide
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. containing bactericides and calcium carbonate)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:104371 CAPLUS
DN 130:293835
TI Reversed-phase thin-layer chromatography with different stationary phases in studies of quantitative structure-biological activity relationship of new antimycotic compounds
AU Rozylo, Jan K.; Zabinska, Anna; Matysiak, Joanna; Niewiadomy, Andrzej
CS Faculty of Chemistry, M. Curie-Sklodowska University, Lublin, 20-031, Pol.
SO Journal of AOAC International (1999), 82(1), 31-37
CODEN: JAINEE; ISSN: 1060-3271
PB AOAC International, Inc.
DT Journal
LA English
AB Reversed-phase thin-layer chromatog. with RP-8, RP-18, and RP-18W stationary phases was used in quant. structure-activity relation (QSAR) studies of new antimycotic compds. The retention behavior of 10 dihydroxythiobenzanilides was examined for acquisition of log k' data. With water-acetone mixts. as the mobile phases, the concentration range for which the correlation between log k' and acetone concentration is linear was established for each stationary phase and used to determine hydrophobicity parameters log k'w by linear extrapolation. The effect of substituents on retention consts. was quantitated by using the group contribution parameters cw. On the basis of QSAR equations obtained from these studies, log k'w data can be used to predict antifungal activities of dihydroxythiobenzanilides with satisfactory accuracy.
IT 181875-13-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reversed-phase thin-layer chromatog. with different stationary phases in studies of quant. structure-biol. activity relationship of new dihydroxythiobenzanilide antimycotic compds.)
RN 181875-13-8 CAPLUS
CN Benzenecarbothioamide, 2,4-dihydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:42569 CAPLUS
DN 130:95392
TI Preparation of bis-amides of 1,2-benzenediamines as antithrombotic agents
IN Beight, Douglas Wade; Craft, Trelia Joyce; Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Klimkowski, Valentine Joseph; Kyle, Jeffrey Alan; Masters, John Joseph; Mendel, David; Milot, Guy; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 311 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9900121	A1	19990107	WO 1998-US13427	19980626 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2294042	AA	19990107	CA 1998-2294042	19980626 <--
AU 9882708	A1	19990119	AU 1998-82708	19980626 <--
EP 1014962	A1	20000705	EP 1998-932928	19980626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002512633	T2	20020423	JP 1999-505829	19980626
US 6313122	B1	20011106	US 2000-445972	20000320
US 2002120007	A1	20020829	US 2001-961164	20010921
US 6605626	B2	20030812		
PRAI US 1997-50894P	P	19970626		
WO 1998-US13427	W	19980626		
US 2000-445972	A3	20000320		

OS MARPAT 130:95392
GI



I II

AB The title compds. [I; A3-A6 together with the two carbons to which they are attached = (un)substituted benzene wherein A3 = CR3; A4 = CR4; A5 = CR5; A6 = CR6; R3 = H, OH, OCH2Ph, etc.; R4, R5 = H, Me, halo, etc.; R6 = H, F, OH, etc.; two adjacent residues selected from R3-R6 together form a benzene ring, and the other two are hydrogen; L1 = NHCO, OCO, CONH; Q1 = (un)substituted Ph, 2-furanyl, 2-thienyl, etc.; R2 = (un)substituted NHCOPh, OCOPh, CH2OPh, etc.], useful as inhibitors of factor Xa (no data), were prepd. and formulated. Thus, treatment of N-benzylisonipecotate with oxalyl chloride in CH2Cl2 followed by addn. of DMF, and subsequent addn. of the resulting mixt. into a soln. of N1-(4-methoxybenzoyl)-1,2-benzenediamine and pyridine in CH2Cl2 and THF afforded 54% II. Compds. I are effective at 0.01-1000 mg/kg/day.

IT 87-17-2, N-Phenylsalicylamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bis-amides of 1,2-benzenediamines as antithrombotic agents)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:646666 CAPLUS
DN 130:22727
TI Antifungal and antibacterial activity of silicon and tin compounds
AU Saini, R. K.; Kumar, Ashwani
CS Department of Botany, University of Rajasthan, Jaipur, 302 004, India
SO Journal of Phytological Research (1997), 10(1-2), 141-144
CODEN: JPHREO; ISSN: 0970-5767
PB Phytological Society
DT Journal
LA English
AB Biochem. aspects of some organosilicon and organotin complexes of salicylanilide (sal. anil) and its thiosemicarbazone (sal. anil. TSCZ) have been described. The ligand and their organo complexes have been tested in vitro against a number of pathogenic fungi (Alternaria brassicicola, Macrophomina phaseolina, Fusarium oxysporum) and bacteria (Xanthomonas campestris, Pseudomonas pisi, Escherichia coli and Staphylococcus aureus) at different concns. and were found to possess remarkable fugicidal and bactericidal properties. Tin compds. showed better activity than silicon complexes.

IT 87-17-2, Salicylanilide 189443-19-4
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antifungal and antibacterial activity of silicon and tin compds.)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 189443-19-4 CAPLUS
CN Benzenecarboximidic acid, 2-hydroxy-N-phenyl-, 2-(aminothioxomethyl)hydrazide (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:613444 CAPLUS
DN 129:265466
TI Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
IN Maycock, Alan L.; Chang, An-chih; Farrar, John J.; Balogh, Imre
PA Adolor Corp., USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5811078	A	19980922	US 1997-818559	19970314 <--
US 5798093	A	19980825	US 1997-892389	19970714 <--
PRAI US 1997-818559	A2	19970314		

OS MARPAT 129:265466
AB Spray formulations of anti-hyperalgesic opiates comprise an anti-hyperalgesic opiate having a peripheral selectivity of 251 to 1,280 in an aqueous alc. mixture containing up to 15% ethanol, propanol, and/or isopropanol. Thus, 100 g of 4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutyramide was dissolved in 2 L of a 5 % ethanol/95 % water mixture with agitation and the solution was transferred to a pump action spray bottle.

IT 87-17-2, Salicylanilide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical sprays containing anti-hyperalgesic opiates and active ingredients to promote wound healing)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:513134 CAPLUS
DN 129:230511
TI Synthesis and biological properties of chorosalicylamide derivatives
AU Truong, Phuong; Mai, Phuong Mai; Tran, Thanh Dao; Nguyen, Dinh Nga; Nguyen, Thi Van Ha; Nguy, Thi Thuy Nhung
CS Vietnam
SO Tap Chi Duoc Hoc (1998), (5), 8-12
CODEN: TCDHDQ; ISSN: 0258-6967
PB Tap Chi Duoc Hoc
DT Journal
LA Vietnamese
AB 4-Chloroaniline, 5-chlorosalicylic acid and 3,5-dichlorosalicylic acid were obtained by chlorination of aniline and salicylic acid. Chlorosalicylanilide derivs. were then prepared Chlorosalicylanilide derivs. have high antibacterial and antifungal activity and show low toxicity.
IT **4638-48-6P**, 5-Chlorosalicylanilide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and biol. properties of chorosalicylamide derivs.)
RN 4638-48-6 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:479029 CAPLUS
DN 129:122458
TI Preparation of N,N'-diphenylurea derivatives as interleukin-8 receptor antagonists
IN Widdowson, Katherine Louisa; Veber, Daniel Frank; Jurewicz, Anthony Joseph; Hertzberg, Robert Philip; Rutledge, Melvin Clarence, Jr.
PA Smithkline Beecham Corporation, USA
SO U.S., 50 pp., Cont.-in-part of U.S. Ser. No. 641,990.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5780483	A	19980714	US 1996-701299	19960821 <--
	US 5886044	A	19990323	US 1996-641990	19960320 <--
	US 6211373	B1	20010403	US 1998-111663	19980708
PRAI	US 1995-390260	B2	19950217		
	US 1996-641990	A2	19960320		
	WO 1996-US2260	W	19960216		
	US 1996-701299	A3	19960821		

OS MARPAT 129:122458
GI



I

AB The title compds. [I; X = O, S; R = any functional moiety having an ionizable H and a pKa of ≤10 (sic); R1, Y = H, halo, NO2, cyano, (halo)alkyl, alkenyl, (halo)alkoxy, N3, HO, hydroxyalkyl, aryl, arylalkyl, aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, arylalkanyl, heteroarylalkenyl, (un)substituted NH2, CONH2, or SO3H, etc.; m, n = 1-3], which are useful for the treatment of disease states mediated by the chemokine, interleukin-8 (IL-8) (no data), are prepared Thus, Me 4-amino-3-hydroxybenzoate was added to a solution of Ph isocyanate in PhMe and the resulting mixture was stirred at .apprx.80° for 24-48 h to give 90% N-[2-hydroxy-4-(methoxycarbonyl)phenyl]-N'-phenylurea.
IT **182499-16-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N,N'-diphenylurea derivs. as interleukin-8 receptor antagonists for disease treatment)
RN 182499-16-7 CAPLUS
CN Benzamide, 3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **87-17-2**, 2-Phenylaminocarbonylphenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N,N'-diphenylurea derivs. as interleukin-8 receptor antagonists for disease treatment)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



IT **1214-44-4P**, 2-Amino-6-(phenylaminocarbonyl)phenol
68507-91-5P, 2-Nitro-6-(phenylaminocarbonyl)phenol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N,N'-diphenylurea derivs. as interleukin-8 receptor antagonists for disease treatment)
RN 1214-44-4 CAPLUS
CN Benzamide, 3-amino-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 68507-91-5 CAPLUS
CN Benzamide, 2-hydroxy-3-nitro-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:450921 CAPLUS
DN 129:197560
TI Substituted Salicylanilides as Inhibitors of Two-Component Regulatory Systems in Bacteria
AU Macielag, Mark J.; Demers, James P.; Fraga-Spano, Stephanie A.; Hlasta, Dennis J.; Johnson, Sigmond G.; Kanojia, Ramesh M.; Russell, Ronald K.; Sui, Zhihua; Weidner-Wells, Michele A.; Werblood, Harvey; Foleno, Barbara D.; Goldschmidt, Raul M.; Loeloff, Michael J.; Webb, Glenda C.; Barrett, John F.
CS R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, 08869, USA
SO Journal of Medicinal Chemistry (1998), 41(16), 2939-2945
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB A new class of inhibitors of the two-component regulatory systems (TCS) of bacteria was discovered based on the salicylanilide screening hits, closantel and tetrachlorosalicylanilide. A systematic SAR study vs. a model TCS, KinA/Spo0F, demonstrated the importance of electron-attracting substituents in the salicyloyl ring and hydrophobic groups in the anilide moiety for optimal activity. In addition, derivs. containing the 2,3-dihydroxybenzanilide structural motif, were potent inhibitors of the autophosphorylation of the KinA kinase, with IC50s of 2.8 and 6.3 μM, resp. Compound 8 also inhibited the TCS mediating vancomycin resistance (VanS/VanR) in a genetically engineered Enterococcus faecalis cell line at concns. subinhibitory for growth. Closantel, tetrachlorosalicylanilide, and several related derivs. had antibacterial activity against the drug-resistant organisms, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF).
IT **4214-48-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria)
RN 4214-48-6 CAPLUS
CN Benzamide, 3,5-dichloro-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:352307 CAPLUS
DN 129:87959
TI Silver halide photographic materials for medical x-ray films
IN Toma, Yasuo
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10148905	A2	19980602	JP 1996-310622	19961121 <--
PRAI JP 1996-310622		19961121		

AB In the title materials having ≥1 Ag halide emulsion layer on ≥1 side of a support, ≥50% of the total projected area of the Ag halide grains used are tabular twinned crystal grains whose average AgI content is ≤2.0 mol% and in which dislocation lines are present in the vicinity of the tops and/or at the edges of the grains and the emulsion layer contains a leuco compound that provides a blue dye upon reaction with oxidized developing agents. The materials show stable developability in rapid processing and provide high-quality images with neutral black image tone.
IT 209391-51-5
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(silver halide photog. emulsion containing leuco dye for rapid-processing medical x-ray films)
RN 209391-51-5 CAPLUS
CN Benzamide, 5-[[4-(dimethylamino)phenyl]amino]-2-hydroxy-4-[(1-oxotetradecyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:193672 CAPLUS
DN 128:255057
TI Synthesis and assay of antifungal and antibacterial effects of iodosalicylanilide compounds
AU Truong, Phuong; Tran, Thanh Dao
CS School of Medicine and Pharmacology, Ho Chi Minh City, Vietnam
SO Tap Chi Duoc Hoc (1997), (10), 7-10
CODEN: TCDHDQ; ISSN: 0258-6967
PB Tap Chi Duoc Hoc
DT Journal
LA Vietnamese
AB Direct iodination of aniline and salicylic acid gave 4-iodoaniline and 5-iodosalicylic acid. 4-Aminosalicylic acid was diazotized and substituted by iodine to obtain 4-iodosalicylic acid. 4'-Iodosalicylanilide, 5-iodosalicylanilide, 4-iodosalicylanilide, and 4,4'-diiodosalicylanilide were prepared Antibiotic and antifungal activities were determined
IT 2441-58-9P 19503-61-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antifungal and antibacterial activities of iodosalicylanilides)
RN 2441-58-9 CAPLUS
CN Benzamide, 2-hydroxy-5-iodo-N-phenyl- (9CI) (CA INDEX NAME)



RN 19503-61-8 CAPLUS
CN Benzamide, 2-hydroxy-4-iodo-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:89679 CAPLUS
DN 128:178048
TI Relationships between the chemical structure of antimycobacterial substances and their activity against atypical strains. Part 14. 3-aryl-6,8-dihalogeno-2H-1,3-benzoxazine-2,4(3H)-diones
AU Waisser, Karel; Hladuvkova, Jana; Gregor, Jiri; Rada, Tomas; Kubicova, Lenka; Klimesova, Vera; Kaustova, Jarmila
CS Department Inorganic Organic Chemistry, Faculty Pharmacy, Hradec Kralove, 50005, Czech Rep.
SO Archiv der Pharmazie (Weinheim, Germany) (1998), 331(1), 3-6
CODEN: ARPMAS; ISSN: 0365-6233
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
AB A set of 8 derivs. of 6,8-dichloro-3-phenyl-2H-benzoxazine-2,4(3H)-dione and 9 derivs. of 6,8-dibromo-3-phenyl-2H-1,3-benzoxazine-2,4(3H)-dione, substituted on the Ph ring, was prepared by the reaction of the corresponding salicylanilides with Et chloroformate. The compds. were evaluated in vitro for antimycobacterial activity against Mycobacterium tuberculosis, Mycobacterium kansasii, and Mycobacterium avium. Their activity increases with increasing hydrophobicity and electron-withdrawing ability of the substituents on the Ph ring.
IT 2577-72-2P 4214-48-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoxazinediones with antimycobacterial activity)
RN 2577-72-2 CAPLUS
CN Benzamide, 3,5-dibromo-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 4214-48-6 CAPLUS
CN Benzamide, 3,5-dichloro-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:13809 CAPLUS
DN 128:80061
TI Wide range cleaning and disinfecting preparations
IN Abraham, Weitzman
PA Abraham, Weitzman, Israel
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9747200	A1	19971218	WO 1997-IL168	19970525 <--
W: AU, CA, CH, CN, DE, DK, ES, FI, GB, JP, KR, NO, NZ, SE, SG, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9727868	A1	19980107	AU 1997-27868	19970525 <--
PRAI IL 1996-118609	A	19960609		
WO 1997-IL168	W	19970525		

AB A group of wide range germicidal action disinfecting prepns. for hospital and laboratory surfaces and medical equipment is given, each preparation comprising one or more bleaching agent in combination with at least one compound of fungicidal activity. The same prepns. may be diluted for household use and they may be prepared as liquid solns., aerosols, humidifiers in cleansing tissues, ointments with a suitable emulsifier or in dry powder formulation, on their own or in admixt. with other disinfectants or as an addition to soaps or detergents. The prefered bleaching agent is an alkali or alkaline-earth hypohalide. Thus, a preparation contains NaClO, 2,3,4,6-tetrachlorophenol, detergent and water.
IT 87-17-2, Salicylanilide
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cleaning and disinfecting prepns. containing)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:708565 CAPLUS
DN 127:346202
TI N-phenylglycinolphenylacetamides as antiatherosclerotic agents
IN Goldmann, Siegfried; Mueller, Ulrich; Connell, Richard; Bischoff, Hilmar; Denzer, Dirk; Gruetzmann, Rudi; Beuck, Martin
PA Bayer A.-G., Germany
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19615263	A1	19971023	DE 1996-19615263	19960418 <--
	EP 802186	A1	19971022	EP 1997-105721	19970407 <--
	EP 802186	B1	20001129		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 197794	E	20001215	AT 1997-105721	19970407
	ES 2153141	T3	20010216	ES 1997-105721	19970407
	PT 802186	T	20010430	PT 1997-105721	19970407
	JP 10059915	A2	19980303	JP 1997-106822	19970410 <--
	US 5750783	A	19980512	US 1997-833824	19970410 <--
	CA 2202704	AA	19971018	CA 1997-2202704	19970415 <--
	GR 3035371	T3	20010531	GR 2001-400198	20010206
PRAI	DE 1996-19615263	A	19960418		

OS MARPAT 127:346202
GI



I



II

AB Title compds. I [A= (un)substituted carbocyclic, Ph, heterocyclic; X = bond, CO; D, E = H, cycloalkyl, N3, OH, halogen, alkyl, alkoxy, alkenyl; R1 = cycloalkyl, alkyl; R2 = H, alkyl; R3 = H, CH2OH; R4 = (un)substituted Ph] were prepared for use as antiatherosclerotic agents (no data). Thus,

L6 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
tert-Bu 2-(4-hydroxyphenyl)-2-cyclopentylacetate was 3-chlorobenzylated, hydrolyzed, and amidated with (R)-HOCH2CHPhNH2 to give the amide II.
IT 198332-46-6P 198332-47-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenylglycinolphenylacetamides as antiatherosclerotic agents)
RN 198332-46-6 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-N-(2-hydroxy-1-phenylethyl)-4-[[2-[(phenylamino)carbonyl]phenyl]methoxy]-, [N(R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198332-47-7 CAPLUS
CN Benzeneacetamide, α-cyclopentyl-4-[[2-[(phenylamino)carbonyl]phenyl]methoxy]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:448091 CAPLUS
DN 127:60605
TI Use of nuclear magnetic resonance to design ligands to target biomolecules
IN Fesik, Stephen W.; Hajduk, Philip J.; Olejniczak, Edward T.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9718469	A2	19970522	WO 1996-US18312	19961113 <--
	WO 9718469	A3	19970807		
	W: AU, CA, IL, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5891643	A	19990406	US 1995-558633	19951114 <--
	CA 2237336	AA	19970522	CA 1996-2237336	19961113 <--
	AU 9676804	A1	19970605	AU 1996-76804	19961113 <--
	AU 711092	B2	19991007		
	EP 870197	A2	19981014	EP 1996-939709	19961113 <--
	EP 870197	B1	20010530		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 2002510384	T2	20020402	JP 1997-519086	19961113
	JP 3300366	B2	20020708		
	IL 123572	A1	20040601	IL 1996-123572	19961113
	IL 149512	A1	20040601	IL 1996-149512	19961113
	IL 149513	A1	20040601	IL 1996-149513	19961113
	IL 149514	A1	20040601	IL 1996-149514	19961113
	IL 149515	A1	20040601	IL 1996-149515	19961113
	GR 3036454	T3	20011130	GR 2001-401304	20010827
PRAI	US 1995-558633	A	19951114		
	US 1996-678903	A	19960712		
	US 1996-744701	A	19961031		
	IL 1996-123572	A3	19961113		
	WO 1996-US18312	W	19961113		

AB The present invention provides a process of designing compds. which bind to a specific target mol. The process includes the steps of a) identifying a first ligand to the target mol. using two-dimensional 15N/1H NMR correlation spectroscopy; b) identifying a second ligand to the target mol. using two-dimensional 15N/1H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target mol.; d) determining the three-dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target mol.; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.
IT 87-17-2
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(use of NMR to design ligands to target biomols.)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:332024 CAPLUS
DN 126:308827
TI Peripherally active anti-hyperalgesic opiates
IN Yaksh, Tony L.; Farrar, John J.; Maycock, Alan L.; Lewis, Michael E.; Dow, Gordon J.
PA Regents of the University of California, USA; Adolor Corporation
SO PCT Int. Appl., 317 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9709973	A2	19970320	WO 1996-US14727	19960912 <--
WO 9709973	A3	19970605		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
US 5849761	A	19981215	US 1995-528510	19950912 <--
CA 2229814	AA	19970320	CA 1996-2229814	19960912 <--
CA 2229814	C	20011204		
CA 2356097	AA	19970320	CA 1996-2356097	19960912 <--
AU 9670710	A1	19970401	AU 1996-70710	19960912 <--
AU 727982	B2	20010104		
EP 852494	A2	19980715	EP 1996-931567	19960912 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9610345	A	19990601	BR 1996-10345	19960912 <--
JP 11512438	T2	19991026	JP 1997-512136	19960912 <--
JP 3553083	B2	20040811		
JP 2002069004	A2	20020308	JP 2001-224729	19960912
NO 9800700	A	19980512	NO 1998-700	19980219 <--
PRAI US 1995-528510	A	19950912		
CA 1996-2229814	A3	19960912		
JP 1997-512136	A3	19960912		
WO 1996-US14727	W	19960912		

OS MARPAT 126:308827
AB Compns. and methods using the compns. for treatment of peripheral hyperalgesia are provided. The compns. contain an anti-hyperalgesia effective amount of one or more compds. that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit substantial central nervous system effects. The anti-diarrheal compound loperamide-HCl is preferred for use in the compns. and methods.
IT 87-17-2, Salicylanilide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peripherally active anti-hyperalgesic opiates)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:199145 CAPLUS
DN 126:203606
TI Consolidation of drug regulations
AU Hubbard, William K.
CS Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, 20855, USA
SO Federal Register (1997), 62(50), 12083-12085, 14 Mar 1997
CODEN: FEREAC; ISSN: 0097-6326
PB Superintendent of Documents
DT Journal
LA English
AB A list of drugs, previously determined by rule-making to be new drugs, is consolidated into one section, under the Federal Food, Drug, and Cosmetic Act. This document also removes the sections now providing for these drugs, except for certain information in the regulations that FDA considers to be necessary. This action, which will make the regulations more concise and efficient, is being taken in response to the President's regulatory reinvention initiative (REGO).
IT 2577-72-2, Metabromsalan 7426-07-5, Tetrachlorosalicylanilide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stds. for new drugs)
RN 2577-72-2 CAPLUS
CN Benzamide, 3,5-dibromo-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 7426-07-5 CAPLUS
CN Benzamide, 2,3,4,5-tetrachloro-6-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:643902 CAPLUS
DN 125:275430
TI Preparation of N,N'-diphenylurea derivatives as interleukin-8 receptor antagonists
IN Widdowson, Katherine Louise; Veber, Daniel Frank; Jurewicz, Anthony Joseph; Rutledge, Melvin Clarence, Jr.; Hertzberg, Robert Philip
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9625157	A1	19960822	WO 1996-US2260	19960216 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 809492	A1	19971203	EP 1996-906547	19960216 <--
R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
JP 11503110	T2	19990323	JP 1996-525199	19960216 <--
CA 2432662	AA	19970821	CA 1996-2432662	19960821 <--
WO 9729743	A1	19970821	WO 1996-US13632	19960821 <--
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9669007	A1	19970902	AU 1996-69007	19960821 <--
AU 725456	B2	20001012		
EP 896531	A1	19990217	EP 1996-929723	19960821 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1215990	A	19990505	CN 1996-180245	19960821 <--
JP 2000504722	T2	20000418	JP 1997-529318	19960821
NZ 316710	A	20000526	NZ 1996-316710	19960821
BR 9612779	A	20001024	BR 1996-12779	19960821
US 6005008	A	19991221	US 1997-894291	19970815 <--
US 6211373	B1	20010403	US 1998-111663	19980708
NO 9803737	A	19981014	NO 1998-3737	19980814 <--
US 6180675	B1	20010130	US 1999-240354	19990129
PRAI US 1995-390260	A2	19950217		
WO 1996-US2260	W	19960216		
US 1996-641990	A3	19960320		
CA 1996-2245927	A3	19960821		
US 1996-701299	A3	19960821		
WO 1996-US13632	W	19960821		

OS MARPAT 125:275430
GI



I

AB The title compds. [I; X = O, S; R = any functional moiety having an ionizable H and a pKa of ≤10; R1, Y = H, halo, NO2, cyano, C1-10

L6 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(halo)alkyl, C2-10 alkenyl, C1-10 (halo)alkoxy, N3, HO, C1-4 hydroxyalkyl, aryl, aryl-C1-4 alkyl, aryloxy, aryl-C1-4 alkoxy, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclyl-C1-4 alkyl, heterocyclyl-C1-4 alkoxy, aryl-C2-10 alkenyl, heteroaryl-C2-10 alkenyl, (un)substituted NH2, carbamoyl, or SO3H, etc.; m, n = 1-3], which are useful for the treatment of disease states mediated by the chemokine, interleukin-8 (IL-8) (no data), are prepd. The chemokine-mediated disease is selected from psoriasis or atopic dermatitis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram neg. sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, thrombosis, Alzheimer's disease, graft vs. host reaction, and allograft rejections. Thus, 1.19 mmol Me 4-amino-3-hydroxybenzoate was added to a soln. of 1.19 mmol Ph isocyanate in toluene and the resulting mixt. was stirred at .apprx.80° for 24-48 h to give 90% N-[2-hydroxy-4-(methoxycarbonyl)phenyl]-N'-phenylurea.

IT **182499-16-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N,N'-diphenylurea derivs. as interleukin-8 receptor antagonists for disease treatment)

RN 182499-16-7 CAPLUS

CN Benzamide, 3-[[[(2-bromophenyl)amino]carbonyl]amino]-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



IT **87-17-2**, 2-Phenylaminocarbonylphenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N,N'-diphenylurea derivs. as interleukin-8 receptor antagonists for disease treatment)

RN 87-17-2 CAPLUS

CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



IT **1214-44-4P**, 2-Amino-6-(phenylaminocarbonyl)phenol
68507-91-5P, 2-Nitro-6-(phenylaminocarbonyl)phenol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L6 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of N,N'-diphenylurea derivs. as interleukin-8 receptor antagonists for disease treatment)

RN 1214-44-4 CAPLUS

CN Benzamide, 3-amino-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 68507-91-5 CAPLUS

CN Benzamide, 2-hydroxy-3-nitro-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:513596 CAPLUS
DN 125:167581
TI Preparation of hydroxybenzamide derivatives as prevention and treatment agents for bone diseases
IN Nomoto, Takashi; Kawakami, Kumiko; Akagawa, Akiko; Matsuyama, Kenji; Torigoe, Koichiro
PA Banyu Pharma Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 08143525	A2	19960604	JP 1994-311235	19941121 <--
PRAI JP 1994-311235		19941121		

OS MARPAT 125:167581
GI



I

AB The title bone disease inhibitors contain a compound (I) [R1 = H, halo, OH, NO2, lower alkyl, lower alkoxy; R2 = H, lower alkyl; n = 0-3; A = aryl, heteroaryl; A and R2 may combine to complete piperidine or tetrahydroisoquinoline ring]. I is an efficient component for prevention and treatment of bone diseases caused by Vacuolar ATPase. Thus, 2,3,4-tribenzyloxybenzoic acid was reacted with aniline in the presence of 4-dimethylaminopyridine and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, followed by hydrogenation to give I [R1 = OH; R2 = H; n = 0; A = Ph], 4 μM of which showed Vacuolar ATPase inhibiting activity of 97%.

IT **180205-89-4P 180205-97-4P 180206-11-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of hydroxybenzamide derivs. as Vacuolar ATPase inhibitors)

RN 180205-89-4 CAPLUS

CN Benzamide, 2,3,4-trihydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 180205-97-4 CAPLUS

CN Benzamide, N-(4,5-dihydro-1H-imidazol-2-yl)-2,3,4-trihydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 180206-11-5 CAPLUS

CN Benzamide, 2,3,4-trihydroxy-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 33 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:452704 CAPLUS
DN 125:123310
TI Antimicrobial oral composition
IN Gaffar, Abdul; Nabi, Nuran; Afflitto, John
PA Colgate Palmolive Co., USA
SO U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 161,033.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5531982	A	19960702	US 1994-275469	19940714	<--
	US 4894220	A	19900116	US 1988-291712	19881229	<--
	US 5043154	A	19910827	US 1989-346258	19890501	<--
	US 5032386	A	19910716	US 1989-398566	19890825	<--
	US 5037637	A	19910806	US 1989-447745	19891208	<--
	GB 2257362	A1	19930113	GB 1992-16778	19891221	<--
	GB 2257362	B2	19930901			
	IN 173759	A	19940709	IN 1989-DE1224	19891221	<--
	CN 1049669	A	19910306	CN 1989-109649	19891228	<--
	CN 1026005	B	19940928			
	ES 2023297	A6	19920101	ES 1989-4397	19891228	<--
	IN 173866	A	19940730	IN 1990-DE119	19900212	<--
	GB 2230187	A1	19901017	GB 1990-7573	19900404	<--
	GB 2230187	B2	19910710			
	GB 2230188	A1	19901017	GB 1990-7574	19900404	<--
	GB 2230188	B2	19910710			
	GB 2230189	A1	19901017	GB 1990-7575	19900404	<--
	GB 2230189	B2	19910710			
	US 5178851	A	19930112	US 1991-655571	19910214	<--
	US 5080887	A	19920114	US 1991-741910	19910808	<--
	US 5192530	A	19930309	US 1991-754887	19910906	<--
	IN 177709	A	19970215	IN 1991-DE1171	19911128	<--
	IN 178924	A	19970719	IN 1991-DE1169	19911128	<--
	IN 179787	A	19971206	IN 1991-DE1170	19911128	<--
	US 5292526	A	19940308	US 1992-966104	19921023	<--
	US 5344641	A	19940906	US 1992-981723	19921125	<--
	CA 1328081	A2	19940329	CA 1993-616610	19930401	<--
	CA 1328623	A2	19940419	CA 1993-616608	19930401	<--
	ZA 9303908	A	19950903	ZA 1993-3908	19930603	<--
	AU 9340058	A1	19931223	AU 1993-40058	19930604	<--
	AU 665422	B2	19960104			
	BR 9302362	A	19940111	BR 1993-2362	19930615	<--
	EP 579383	A1	19940119	EP 1993-304646	19930615	<--
	EP 579383	B1	19970903			
	R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, LU, NL, SE					
	AT 157533	E	19970915	AT 1993-304646	19930615	<--
	IN 180504	A	19980214	IN 1993-DE636	19930623	<--
	CA 1339301	A1	19970819	CA 1993-616760	19931104	<--
	CA 1339301	A2	19970819			
	US 5538715	A	19960723	US 1993-161033	19931203	<--
	US 5686064	A	19971111	US 1994-187984	19940128	<--
	AU 9523262	A1	19960125	AU 1995-23262	19950626	<--
	AU 703912	B2	19990401			
	ZA 9505520	A	19970103	ZA 1995-5520	19950703	<--

L6 ANSWER 33 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

	EP 696449	A2	19960214	EP 1995-201904	19950711	<--
	EP 696449	A3	19961106			
	EP 696449	B1	20011031			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE					
	AT 207731	E	20011115	AT 1995-201904	19950711	
	CA 2153762	AA	19960115	CA 1995-2153762	19950712	<--
PRAI	US 1987-8901	B2	19870130			
	US 1988-291712	A2	19881229			
	US 1989-346258	B2	19890501			
	US 1989-398566	A1	19890825			
	US 1989-398606	B1	19890825			
	US 1991-655571	A3	19910214			
	US 1991-754887	A3	19910906			
	US 1992-981723	A3	19921125			
	US 1993-161033	A2	19931203			
	IN 1987-DE1148	A1	19871230			
	GB 1988-1773	A3	19880127			
	CA 1988-557661	A3	19880129			
	US 1989-398605	B1	19890825			
	GB 1989-28878	A	19891221			
	IN 1989-DE1223	A1	19891221			
	US 1991-657885	A3	19910219			
	US 1992-899412	A	19920616			
	US 1992-966104	A3	19921023			
	US 1994-275469	A	19940714			

AB A oral composition which inhibits plaque formation and reduces gingivitis and caries comprising a water insol. noncationic antimicrobial agent, such as triclosan and an acid reducing agent, such as xylitol. The composition is a dentifrice containing a silica polishing agent. Thus, a dental gel contained triclosan 0.3, xylitol 10.0, Na lauryl sulfate 0.6, flavor 1.0, κ-carrageenan 0.65, Na-CMC 2.0, glycerin 20.0, propylene glycol 0.5, Sylox 15 0.5, sorbitol 15.0, tauranol 0.25, sodium saccharin 0.2, NaF 0.243, and water qs to 100%.
IT 87-17-2D, Salicylanilide, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial dentifrices containing acid reducing agents)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:169192 CAPLUS
DN 124:242346
TI Covalent bonding of active agents to skin, hair or nails by transglutaminase for pharmaceutical and cosmetic compositions
IN Richardson, Norman K.; Schilling, Kurt M.; Pocalyko, David J.; Bailey, Peter L.
PA Chesebrough-Pond's USA Co., USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5490980	A	19960213	US 1994-314178	19940928	<--
PRAI	US 1994-314178		19940928			

OS MARPAT 124:242346
AB Transglutaminase crosslinks proteins by catalyzing the formation of isopeptide bonds between lysine and glutamine residues. Transglutaminase may be used to crosslink beneficial actives containing an amine moiety to glutamine residues in skin, hair or nails. A variety of beneficial actives, e.g., sunscreens, antimicrobial compds., skin conditioning agents, hair conditioning agents, anti-inflammatory compds., antioxidants, coloring agents, perfumes, insect repellents, can thus be delivered to human skin, hair, or nails. Human corneocytes treated with cadaverine (I) and transglutaminase contained 55.0 as compared to 17.4 pmol I/mg cells in controls treated with only I. A skin lotion contained hyaluronic acid 1.5, transglutaminase 1.0, perfumes 0.1, hydroxyethyl cellulose 0.4, absolute ethanol 25, p-Me benzoate 0.2, and water q.s. 100%.
IT 87-17-2, Salicylanilide
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(covalent bonding of active agents to skin, hair or nails)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 35 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:958368 CAPLUS
DN 123:349897
TI Method for evaluation of topical preparations for skin roughness improvement
IN Kashibuchi, Nobuo
PA Pola Kasei Kogyo Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	JP 07253426	A2	19951003	JP 1994-42803	19940314	<--
PRAI	JP 1994-42803		19940314			

AB A method for evaluation of topical prepns. for skin roughness improvement involves: application of topical prepns. (e.g. cosmetics) to the skin of a test subject, application of a dye (e.g. dansyl chloride) on the treated skin, determining the intensity of the fluorescence developed with time, plotting fluorescence intensities with time, and determining the areas under the curves. The method is reliable.
IT 7426-07-5, Tetrachlorosalicyl anilide
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(in evaluation of topical prepns. for skin roughness improvement)
RN 7426-07-5 CAPLUS
CN Benzamide, 2,3,4,5-tetrachloro-6-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:929486 CAPLUS
DN 124:116878
TI Amidinophenoxyalkoxyphenyl derivatives, their manufacture, and use as selective LTB4 receptor antagonists
IN Morrissey, Michael M.; Suh, Hongsuk
PA Ciba-Geigy Corp., USA
SO U.S., 24 pp. Cont.-in-part of U.S. Ser. No. 960, 211, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5451700	A	19950919	US 1992-978004	19921118	<--
	EP 518819	A2	19921216	EP 1992-810423	19920602	<--
	EP 518819	A3	19930421			
	EP 518819	B1	19950802			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE					
	IL 107568	A1	19980104	IL 1993-107568	19931111	<--
	CA 2148930	AA	19940526	CA 1993-2148930	19931112	<--
	WO 9411341	A1	19940526	WO 1993-US10876	19931112	<--
	W: AU, CA, FI, HU, JP, KR, NO, NZ, US					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	AU 9455994	A1	19940608	AU 1994-55994	19931112	<--
	AU 683436	B2	19971113			
	EP 669909	A1	19950906	EP 1994-901395	19931112	<--
	EP 669909	B1	19980107			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	JP 08503466	T2	19960416	JP 1993-512333	19931112	<--
	JP 2795986	B2	19980910			
	HU 72991	A2	19960628	HU 1995-1452	19931112	<--
	HU 218795	B	20001228			
	AT 161826	E	19980115	AT 1994-901395	19931112	<--
	ES 2111896	T3	19980316	ES 1994-901395	19931112	<--
	ZA 9308574	A	19940822	ZA 1993-8574	19931117	<--
	US 5488160	A	19960130	US 1993-164176	19931209	<--
	FI 9502361	A	19950515	FI 1995-2361	19950515	<--
	NO 9501934	A	19950628	NO 1995-1934	19950516	<--
	US 5639768	A	19970617	US 1995-436368	19950725	<--
PRAI	US 1991-714108	B1	19910611			
	EP 1992-810423	A	19920602			
	US 1992-960211	B2	19921013			
	US 1992-978004	A	19921118			
	WO 1993-US10876	W	19931112			

OS MARPAT 124:116878
GI

L6 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB The invention relates to amidines I wherein the C(:NH)NHR3 group may be in tautomeric or isomeric form, R1 is amino which is mono- or disubstituted by a substituent selected from an aliphatic hydrocarbon radical, an araliph. hydrocarbon radical, an aromatic radical, and a cycloaliph. hydrocarbon radical, or is amino which is disubstituted by lower alkylene radical or a said radical interrupted by oxygen; R2 is hydrogen, halogen, trifluoromethyl, an aliphatic hydrocarbon radical, or is hydroxy which is etherified by an aliphatic alc., araliph. alc., or aromatic alc. or which is esterified by an aliphatic or araliph. carboxylic acid; or R2 is hydroxy; or R2 is hydroxy which is etherified by an aliphatic alc. which is substituted by carboxy, by esterified carboxy or by amidated carboxy; R3 is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid; X1 and X3, independently of one another, are oxygen or sulfur; and X2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical; wherein the Ph rings of I may be, independently of one another, further substituted by one or more substituents selected, e.g., halogen, trifluoromethyl; or a pharmaceutically acceptable salt thereof, useful as selective LTB4 receptor antagonists (no data). Thus, e.g., amidation of Et 4-[5-[2-methoxy-4-[N,N-bis(1-methylethyl)aminocarbonyl]phenoxy]pentoxyl]benzenecarboximidoate (preparation given) afforded 4-[5-[4-(aminoiminomethyl)phenoxy]pentoxy]-3-methoxy-N,N-bis(1-methylethyl)benzamide monohydrochloride (II.HCl). Pharmaceutical formulations were given.

IT 172870-54-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(amidinophenoxyalkoxyphenyl derivs., their manufacture, and use as selective LTB4 receptor antagonists)

RN 172870-54-1 CAPLUS
CN Benzamide, 4-[[5-[4-(aminoiminomethyl)phenoxy]pentyl]oxy]-2-hydroxy-N-(1-methylethyl)-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

● HCl

IT 156786-20-8P 156786-21-9P 172870-53-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(amidinophenoxyalkoxyphenyl derivs., their manufacture, and use as selective LTB4 receptor antagonists)

RN 156786-20-8 CAPLUS
CN Benzamide, 2,4-dihydroxy-N-(1-methylethyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 156786-21-9 CAPLUS
CN Benzamide, 4-[[5-(4-cyanophenoxy)pentyl]oxy]-2-hydroxy-N-(1-methylethyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 172870-53-0 CAPLUS
CN Benzenecarboximidic acid, 4-[[5-[3-hydroxy-4-[[(1-methylethyl)phenylamino]carbonyl]phenoxy]pentyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

L6 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:784885 CAPLUS
DN 123:179395
TI Anthelmintic solutions containing salicylanilides for treatment of helminthiasis infections
IN Piskov, Vyacheslav B.; Pushkarev, Aleksandr S.; Kasperovich, Valentina P.; Ponikarov, Aleksandr V.
PA Russia
SO Russ.
From: Izobreteniya 1993, (41-2), 27-8.
CODEN: RUXXE7
DT Patent
LA Russian
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RU 2002460	C1	19931115	RU 1992-5032863	19920318 <--
PRAI	SU 1992-5032863	A	19920318		

AB Title only translated.
IT 87-17-2D, Salicylanilide, derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthelmintic solns. containing salicylanilides for treatment of helminthiasis infections)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:772586 CAPLUS
DN 123:256710
TI (phenylalkyl)imidazoles as angiotensin II antagonists
IN Duncia, John Jonas Vytautas; Ensinger, Carol Lee; Olson, Richard Eric; Quan, Mimi Lifen; Santella, Joseph Basil, III; Vanatten, Mary Katherine
PA Du Pont Merck Pharmaceutical Co., USA
SO PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9428896	A1	19941222	WO 1994-US5717	19940525 <--
	W: AU, BR, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5395844	A	19950307	US 1993-72977	19930610 <--
	CA 2164583	AA	19941222	CA 1994-2164583	19940525 <--
	AU 9472016	A1	19950103	AU 1994-72016	19940525 <--
	EP 711162	A1	19960515	EP 1994-921203	19940525 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08511774	T2	19961210	JP 1994-501827	19940525 <--
	ZA 9403690	A	19951127	ZA 1994-3690	19940526 <--
	US 5545651	A	19960813	US 1994-348843	19941128 <--
PRAI	US 1993-72977	A	19930610		
	WO 1994-US5717	W	19940525		

OS MARPAT 123:256710
GI



AB Novel (phenylalkyl)imidazoles I (R1 = carboxy, carbamoyl, amido, etc.; R2, R3 = H, alkyl, alkoxy, etc.; R6 = alkyl, alkynyl, etc.; R8 = H, halo, etc.; substituent; r = integer) were disclosed as angiotensin II

L6 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
antagonists. An example compd., the {(biphenylyl)methy]imidazolecarboxylate II (potassium salt) was prepd.
IT 167265-17-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (phenylalkyl)imidazole derivs. as angiotensin II antagonists)
RN 167265-17-0 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-ethyl-1-[[3-fluoro-2'-[[[(3-methylbutoxy)carbonyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, [2-[(phenylamino)carbonyl]phenyl]methyl ester, monopotassium salt (9CI) (CA INDEX NAME)



● K

L6 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:444225 CAPLUS
DN 122:205174
TI Synergistic anthelmintic compositions
IN Boray, Joseph Coloman
PA Australian National University, USA; State of New South Wales
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9428887	A1	19941222	WO 1994-AU315	19940614 <--
	W: AU, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9469654	A1	19950103	AU 1994-69654	19940614 <--
	AU 679753	B2	19970710		
	ZA 9404191	A	19950208	ZA 1994-4191	19940614 <--
	EP 710105	A1	19960508	EP 1994-918238	19940614 <--
	EP 710105	B1	20030730		
	R: BE, CH, DE, ES, FR, GB, IE, IT, LI				
PRAI	AU 1993-9339	A	19930615		
	WO 1994-AU315	W	19940614		

AB A method for the control of Fasciola spp. and other helminths in an animal, particularly a ruminant animal, comprises the administration to the animal of at least two anthelmintic-active drugs, optionally together with an acceptable carrier or diluent, to exert a synergistic effect in the animal. The anthelmintic-active drugs are selected from the group consisting of halogenated monophenols or bisphenols, salicylanilides, benzene sulfonamides, halogenated benzimidazoles, benzimidazoles and benzimidazole carbamates. Synergistic compns. comprising these anthelmintic-active drugs are also disclosed. Efficacy of synergistic combinations against F. hepatica are reported.
IT 87-17-2D, Salicylanilide, derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthelmintic synergistic combinations)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:441846 CAPLUS
DN 122:305851
TI Inhibitors of skin-tumor promotion. XIII. Inhibitory effects of euglobals and their related compounds on Epstein-Barr virus activation and on two-stage carcinogenesis of mouse skin tumors. (2)
AU Takasaki, Midori; Konoshima, Takao; Kozuka, Mutsuo; Yoneyama, Koichi; Yoshida, Shigeo; Tokuda, Harukuni; Nishino, Hoyoku; Iwashima, Akio
CS Kyoto Pharm. Univ., Kyoto, 607, Japan
SO Biological & Pharmaceutical Bulletin (1995), 18(2), 288-94
CODEN: BPBLEO; ISSN: 0918-6158
PB Pharmaceutical Society of Japan
DT Journal
LA English
AB One hundred and fifteen synthesized mono, di, and trihydroxybenzamide and thiobenzamide derivs. having structures related to euglobals were examined for their inhibitory effects on Epstein-Barr virus (EBV) activation by 12-O-tetradecanoylphorbol-13-acetate (TPA) as a primary screening test for anti-tumor-promoters. In general, 3-acyl-2,4,6-trihydroxybenzamide and 3-acyl-2,4,6-trihydroxythiobenzamide derivs. exhibited strong or moderate activities, and the latter compds. were less cytotoxic than the former. Meanwhile, little or no activity was observed with mono and dihydroxybenzamide and dihydroxythiobenzamide derivs. Structural requirements for the activities of these compds. have been discussed in detail. Among the above compds., compds. 36 and 73, which were significantly active on the inhibition of EBV activation, were investigated using a two-stage mouse skin carcinogenesis test induced by 7,12-dimethylbenz[a]anthracene (DMBA) and TPA. The results of the in vivo test showed that both compds. have a stronger inhibitory effect than that of the well-known anti-tumor-promoter, glycyrrhetic acid. These results suggested that the two compds. might be valuable as anti-tumor-promoters in chemical carcinogenesis.
IT 111219-79-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(euglobals and related compds. structure-related inhibition of Epstein-Barr virus and skin-tumor promotion)
RN 111219-79-5 CAPLUS
CN Benzamide, 2,4,6-trihydroxy-3-(1-oxopropyl)-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 41 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 41 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:364211 CAPLUS
DN 122:114945
TI controlled-release antiparasitic compositions
IN Hennessy, Desmond Ronald; Ashes, John Richard; Scott, Trevor William; Gulati, Suresh Kumar; Steel, John Winston
PA Commonwealth Scientific and Industrial Research Organization, Australia; Meat Research Corp.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9427598	A1	19941208	WO 1994-AU272	19940524 <--
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2163455	AA	19941208	CA 1994-2163455	19940524 <--
AU 9467902	A1	19941220	AU 1994-67902	19940524 <--
AU 687062	B2	19980219		
BR 9406627	A	19960206	BR 1994-6627	19940524 <--
EP 705101	A1	19960410	EP 1994-916095	19940524 <--
EP 705101	B1	20011219		
R: DE, ES, FR, GB, IT				
ES 2170099	T3	20020801	ES 1994-916095	19940524
ZA 9403647	A	19950127	ZA 1994-3647	19940525 <--
US 5840324	A	19981124	US 1996-549755	19960313 <--
PRAI AU 1993-9030	A	19930526		
WO 1994-AU272	W	19940524		

AB The delivery of anti-parasitic agents to ruminant animals in a controlled manner to enable the agent to have maximum effect on the parasite for longer times than is possible with conventional formulations is described. The compns. comprise a benzimidazole, macrocyclic lactone, organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent, dispersed in a medium the solubility characteristics of which are such as to ensure that, following oral administration, controlled amts. of the anti-parasitic agent become available to the parasite, either directly or by absorption into the ruminant blood plasma, during passage of the composition through the rumen, the abomasum and the intestine. A 3-stage release antiparasitic formulation was prepared from benzimidazole, vegetable oil, emulsification with caseins, freeze-drying and treatment with formalin.
IT 87-17-2, Salicylanilide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release antiparasitic compns.)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:331095 CAPLUS
DN 122:89437
TI Veterinary antimycotic composition
IN Lupea, Alfa Xenia; Decun, Mihai; Oprin, Carsta
PA Institutul Politehnic, Timisoara, Rom.
SO Rom., 3 pp.
CODEN: RUXXA3
DT Patent
LA Romanian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI RO 104280	B1	19931215	RO 1989-137920	19890126 <--
PRAI RO 1989-137920		19890126		

AB An antimycotic composition suitable for use in treatment of trichophytoses of cattle can be prepared which contains 60-100 parts (by weight) salicylanilide, 30-50 parts salicylic acid with or without 27.5 parts sulfur; it can be compounded in the form of an ointment with 822.5-900 parts ointment base, which may include lard, vaseline, or known veterinary excipients, or in the form of a solution with 1160 vols. EtOH. The ointment may be applied to the surface of trichophytic lesions.
IT 87-17-2, Salicylanilide
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(veterinary antimycotic composition)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:264638 CAPLUS
DN 122:306539
TI Novel titanium compounds inhibiting tumor growth, pharmaceutical compositions containing them, and their preparation
IN Bitter, Istvan; Palyi, Istvan; Gaal, Dezso; Csuka, Orsolya; Bodnar, Maria; Kolonics, Zoltan; Soptiei, Csaba; Karacsonyi, Bela; Dioszegine Eichhardt, Erzsebet
PA Nitrokemia Ipartelepek, Hung.; Orszagos Onkologiai Intezet
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9421652	A1	19940929	WO 1994-HU7	19940318 <--
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
HU 66457	A2	19941128	HU 1993-789	19930319 <--
HU 212105	B	19960228		
PRAI HU 1993-789	A	19930319		

OS CASREACT 122:306539
GI



I

AB Organotitanium(IV) compds. R2TiX2 [X = Cl, OEt when R = salicylanilidato, Z; X2 = 2,3-L-ascorbate when R = PhC(O)CH:CMeO] inhibit tumor growth, diminish the degree of immunosuppression, are useful for the treatment of resistant tumors, and induce fewer adverse side effects than other organotitanium derivs. known in the art. They are particularly effective against melanoma and colonic tumors. The compds. are prepared e.g. by reacting salicylanilide or 1-phenyl-3-methyl-4-acetylpyrazolone with TiCl4 in an aprotic organic solvent.
IT 87-17-2, Salicylanilide
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel titanium compds. inhibiting tumor growth and their preparation)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:139668 CAPLUS
DN 122:306
TI Balanced angiotensin II receptor antagonists. III. The effects of substitution at the imidazole 5-position
AU Santella, Joseph B., III; Duncia, John V.; Ensinger, Carol L.; VanAtten, Mary K.; Carini, David J.; Wexler, Ruth R.; Chiu, Andrew T.; Wong, Pancras C.; Timmermans, Pieter B. M. W. M.
CS Exptl. Stn., DuPont Merck Pharm. Co., Wilmington, DE, 19880-0402, USA
SO Bioorganic & Medicinal Chemistry Letters (1994), 4(18), 2235-40
CODEN: BMCLE8; ISSN: 0960-894X
DT Journal
LA English
AB We wish to report on a series of substituted Me esters and amides of DMP 811, which bind to both the AT1 and AT2 receptor subtypes. Some of the esters bind well to both receptor subtypes in the subnanomolar range when the optimal acid isostere is present together with an ortho-fluorine substituent on the biphenylmethyl group.
IT 159466-37-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(DMP-811 derivs. as angiotensin II receptor antagonists - effects of substitution at imidazole 5-position)
RN 159466-37-2 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-ethyl-1-[[3-fluoro-2'-[[[(3-methylbutoxy)carbonyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, [2-[(phenylamino)carbonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:139073 CAPLUS
DN 118:139073
TI Biological activity of salicylanilides
AU Kubicova, L.; Waisser, K.
CS Farm. Fak., Univ. Karlovy, Hradec Kralove, Czech.
SO Cesko-Slovenska Farmacie (1992), 41(6), 208-16
CODEN: CKFRAY; ISSN: 0009-0530
DT Journal; General Review
LA Czech
AB A review with 236 refs.
IT 87-17-2D, Salicylanilide, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:197735 CAPLUS
DN 112:197735
TI Synthesis of some new salicylic acid-5-sulfonamides as possible antibacterial and analgesic agents
AU Mohamed, Y. A.; Ammar, Y. A.; El-Sharief, A. M. S.; Hassanin, A. A.
CS Fac. Sci., Al-Azhar Univ., Cairo, Egypt
SO Acta Pharmaceutica Jugoslavica (1989), 39(3), 181-91
CODEN: APJUA8; ISSN: 0001-6667
DT Journal
LA English
OS CASREACT 112:197735
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 5-(Chlorosulfonyl)salicylic acid reacts with p-aminobenzoic acid to give sulfonamide I (R = p-HO2CC6H4) from which primary and secondary amides, e.g., II, have been prepared Reaction of I (R = p-MeCOC6H4) with benzaldehyde produced the cinnamoyl derivative, which converted to the corresponding pyrazoline III, isoxazoline IV, and tetrahydropyrimidine V, resp. The toxic and analgesic effects of the prepared compds. were discussed. The most powerful analgesic effects were found in I (R = p-MeCOC6H4, Q) and VI.
IT 123532-06-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic activity of)
RN 123532-06-9 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl-5-[[[4-[(phenylamino)carbonyl]phenyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L6 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:587432 CAPLUS
DN 105:187432
TI Antituberculotics. XXXV. 4-Dimethylaminosalicylanilides
AU Waisser, K.; Cech, J.; Machacek, M.; Vanzura, J.; Celadnik, M.; Odlerova, Z.
CS Org. Chem. Farm. Fak., Univ. Karlovy, Hradec Kralove, Czech.
SO Cesko-Slovenska Farmacie (1986), 35(6), 270-3
CODEN: CKFRAY; ISSN: 0009-0530
DT Journal
LA Czech
OS CASREACT 105:187432
GI



I, R1=Br
II, R1=OMe

AB The reaction of 4-dimethylaminosalicylic acid with the corresponding aniline derivs. in pyridine solution in the presence of phosphorus trichloride yielded a series of 4-dimethylaminosalicylanilides, namely 4-dimethylaminosalicylanilide, 4'-bromo-4-dimethylaminosalicylanilide (I), 4'-chloro-4-dimethylaminosalicylanilide, 3',4'-dichloro-4-dimethylaminosalicylanilide, 4'-methoxy-4-dimethylaminosalicylanilide (II), and 4'-methyl-4-dimethylaminosalicylanilide. In the substances prepared, the structure was verified by 1H-NMR spectra and IR spectra (valence vibrations of carbonyl 1600-1650 cm-1). 4-Dimethylaminosalicylanilide was converted by a reaction with Et chloroformiate to 3-phenyl-7-dimethylamino-2H-1,3-benzoxazine-2,4-dione. The melting temps. and results of elemental anal. are given. The minimal inhibition concns. in μmol/L towards Mycobacterium tuberculosis H37Rv and M. kansasii PKG 8 were determined None of the above mentioned substances was active towards M. avium. None of the substances under study is equal to p-aminosalicylic acid (PAS) towards M. tuberculosis. Anilides I and II are, however, in contrast to PAS, also active towards M. kansasii.
IT 27559-70-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and tuberculostatic activity of)
RN 27559-70-2 CAPLUS
CN Benzamide, 4-(dimethylamino)-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1984:563061 CAPLUS
DN 101:163061
TI Salicylanilides in the treatment of helminth diseases
AU Agrawal, V. K.; Sharma, Satyavan
CS Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, India
SO Pharmazie (1984), 39(6), 373-8
CODEN: PHARAT; ISSN: 0031-7144
DT Journal; General Review
LA English
AB A review with 140 refs.
IT 87-17-2D, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthelmintic activity of, in humans and lab animals)
RN 87-17-2 CAPLUS
CN Benzamide, 2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1980:222 CAPLUS
DN 92:222
TI Relationships between anthelmintic effects of drugs against Echinococcus multilocularis in vitro and in vivo
AU Sakamoto, Tsukasa
CS Lab. Vet. Pathol., Kagoshima Univ., Kagoshima, Japan
SO Memoirs of the Faculty of Agriculture, Kagoshima University (1979), 15, 115-23
CODEN: MAKUA6; ISSN: 0453-0853
DT Journal
LA English
AB Generally, halogenized salicylanilide and bisphenol derivs. showed high scolicidal effect when incubated with the protoscoleces of E. multilocularis. The intensity of the scolicidal action of salicylanilide derivs. increased with the addition of halogen atoms. In infected mice injected with the active drugs the same structure activity relation was observed. Injected salicylanilide derivs. in propylene glycol were more effective than orally given drug. Apparently there is a correlation between in vitro and in vivo testing.
IT 2577-72-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthelmintic activity of, structure in relation to)
RN 2577-72-2 CAPLUS
CN Benzamide, 3,5-dibromo-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 50 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1974:66715 CAPLUS
DN 80:66715
TI Pharmacological action of 5-chloro-N-(3-hydroxypropyl)salicylanilide (G264)
AU Orzalesi, G.; Selleri, R.; Caldini, O.; Volpato, I.
CS Soc. Italo-Britannica L. Manetti, H. Roberts e C., Florence, Italy
SO Bollettino Chimico Farmaceutico (1973), 112(6), 409-15
CODEN: BCFAAI; ISSN: 0006-6648
DT Journal
LA Italian
AB Pharmacol. screening showed that 5-chloro-N-(3-hydroxypropyl)salicylanilide (I) [41220-64-8] depressed the spontaneous motility of mice and HOAc-induced abdominal contractions in vivo. However, it was devoid of analgesic activity as measured by thermal and mech. tests. I showed no antiinflammatory action in rats and did not alter, pentetrazole-induced convulsions or hexobarbital sleeping time in mice it had little spasmolytic activity on the isolated guinea pig ileum. I was perfectly tolerated by mice at doses of .leq.1200 mg/kg i.p. and .leq.2000 mg/kg orally.
IT 41220-64-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)
RN 41220-64-8 CAPLUS
CN Benzamide, 5-chloro-2-hydroxy-N-(3-hydroxypropyl)-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1972:54223 CAPLUS
DN 76:54223
TI Effects of substituting tetrazole for carboxyl in two series of antiinflammatory phenoxyacetic acids
AU Drain, D. J.; Davy, B.; Horlington, M.; Howes, J. G. B.; Scruton, J. M.; Selway, R. A.
CS Smith and Nephew Res. Ltd., Gilston Park/Harlow/Essex, UK
SO Journal of Pharmacy and Pharmacology (1971), 23(11), 857-64
CODEN: JPPMAB; ISSN: 0022-3573
DT Journal
LA English
AB Series of 2-benzamidophenoxyacetic acids, 5-(2-benzamidophenoxymethyl)tetrazoles, 2-phenylcarbamoylphenoxyacetic acids, and 5-(2-phenylcarbamoylphenoxymethyl)tetrazoles were synthesized by a variety of methods, generally including the formation of either a benzamidophenoxyacetonitrile or phenylcarbamoylphenoxyacetonitrile intermediate. Antiinflammatory activity was measured by the phenylbenzoquinone writhing test in mice and the rat foot carrageenan edema test. Potency in the 2 o-benzamido substituted series did not correlate with structure. Introduction of substituents into the benzene rings of the o-phenylcarbamoyl substituted series led to complex changes. When the phenoxy ring was unsubstituted, introduction of m- and p-substituents possessing high pos. π consts. into the o-phenylcarbamoyl ring led to increased potency, and each tetrazole was appreciably more potent than the corresponding acid. When the o-phenylcarbamoyl ring was unsubsituted, m and p-substituents with high pos. π consts. introduced in the phenoxy ring increased potency in the acid series but not in the tetrazoles series, and each acid was more potent than the corresponding tetrazole. 5-[2-(3,4-Dichlorophenylcarbamoyl)phenoxymethyl]tetrazole (I) [33952-24-8] and 5-[4-chloro-2-(3-trifluoromethylphenylcarbamoyl)phenoxymethyl]tetrazole [33952-25-9] were the most potent tetrazoles in the mouse writhing test.
IT 35421-53-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 35421-53-5 CAPLUS
CN Benzamide, 5-(1,1-dimethylethyl)-2-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 52 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1971:448722 CAPLUS
DN 75:48722
TI Antiinflammatory phthalic acid monoamides
IN Cahn, Jean; Wermuth, Camille G.; Rottenberg, Eugene
PA Socibre, Nanterre
SO Ger. Offen., 28 pp.
CODEN: GWXXEX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2040578	A	19710225	DE 1970-2040578	19700814 <--
	DE 2040578	B2	19800124		
	DE 2040578	C3	19800918		
	FR 2059977	A5	19710611	FR 1969-28098	19690814 <--
	NL 7012072	A	19710216	NL 1970-12072	19700814 <--
	ZA 7005632	A	19710428	ZA 1970-5632	19700814 <--
	GB 1327227	A	19730815	GB 1970-39265	19700814 <--
	US 3793458	A	19740219	US 1970-63929	19700814 <--
PRAI	FR 1969-28098	A	19690814		

GI For diagram(s), see printed CA Issue.
AB The title dicarboxylic acids (I) are prepared by treatment of phthalic anhydride (II) or 2,3-pyridinedicarboxylic anhydride with PhNH2. Thus, II and 2,6-Me2C6H3NH2 in CH2Cl2 kept 18 hr yielded 48% 2-(2,6-Me2C6H3NHCO)C6H4CO2H, m. 178 ± 1°. Similarly prepared were 22 addnl. analogs.
IT 4727-29-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory activity of)
RN 4727-29-1 CAPLUS
CN Benzoic acid, 2-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)



=>